A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine- 131-rituximab radio-immunotherapy

Haematologica

Volumn 93, Issue 5, 2008, Pages 789-790

  Bishton, Mark J ^a   Hicks, Rodney J ^a   Westerman, David A ^a,b   Prince, Miles H ^a   Wolf, Max ^a   Seymour, John F ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Lymphoma; Molecular remission; PCR; PET; Radio immunotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RITUXIMAB;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LETTER; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 43449099777     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12253     Document Type: Letter

References (10)

1. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-2
2. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9.
3. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005;35:165-75.
4. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 2006;107:175-83.
5. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4418-25.
6. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-8.
7. Joyce JM, Degirmenci B, Jacobs S, McCook B, Avril N. FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. Clin Nucl Med 2005;30:564-8.
8. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
9. Mandigers CM, Meijerink JP, Mensink EJ, Tonnissen EL, Hebeda KM, Bogman MJ, et al. Lack of correlation between numbers of circulating t(14;18)-positive cells and response to first-line treatment in follicular lymphoma. Blood 2001;98:940-4.
10. Darby A, Gribben JG. Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation. Methods Mol Med 2005;115:315-31.